From: ALPHLARD: a Bayesian method for analyzing HLA genes from whole genome sequence data
 |  | ALPHLARD | OptiType | PHLAT | HLA-VBSeq |
---|---|---|---|---|---|
HLA-A | 1st | 100% (50/50) | 100% (50/50) | 76.0% (38/50) | 96.0% (48/50) |
 | 2nd | 98.0% (49/50) | 98.0% (49/50) | 60.0% (30/50) | 82.0% (41/50) |
 | 3rd | 98.0% (49/50) | N/A | 46.0% (23/50) | 82.0% (41/50) |
HLA-B | 1st | 100% (48/48) | 87.5% (42/48) | 72.9% (35/48) | 89.6% (43/48) |
 | 2nd | 100% (48/48) | 85.4% (41/48) | 56.3% (27/48) | 75.0% (36/48) |
 | 3rd | 95.8% (46/48) | N/A | 39.6% (19/48) | 72.9% (35/48) |
HLA-C | 1st | 100% (50/50) | 100% (50/50) | 78.0% (39/50) | 96.0% (48/50) |
 | 2nd | 98.0% (49/50) | 94.0% (47/50) | 56.0% (28/50) | 66.0% (33/50) |
 | 3rd | 98.0% (49/50) | N/A | 44.0% (22/50) | 66.0% (33/50) |
HLA-DPA1 | 1st | 100% (24/24) | N/A | N/A | 87.5% (21/24) |
 | 2nd | 100% (24/24) | N/A | N/A | 87.5% (21/24) |
 | 3rd | 100% (24/24) | N/A | N/A | 87.5% (21/24) |
HLA-DPB1 | 1st | 100% (22/22) | N/A | N/A | 86.4% (19/22) |
 | 2nd | 100% (22/22) | N/A | N/A | 86.4% (19/22) |
 | 3rd | 100% (22/22) | N/A | N/A | 86.4% (19/22) |
HLA-DQA1 | 1st | 100% (24/24) | N/A | 70.8% (17/24) | 100% (24/24) |
 | 2nd | 95.8% (23/24) | N/A | 62.5% (15/24) | 95.8% (23/24) |
 | 3rd | 95.8% (23/24) | N/A | 62.5% (15/24) | 95.8% (23/24) |
HLA-DQB1 | 1st | 100% (18/18) | N/A | 77.8% (14/18) | 100% (18/18) |
 | 2nd | 94.4% (17/18) | N/A | 61.1% (11/18) | 88.9% (16/18) |
 | 3rd | 94.4% (17/18) | N/A | 38.9% (7/18) | 88.9% (16/18) |
HLA-DRB1 | 1st | 100% (24/24) | N/A | 70.8% (17/24) | 95.8% (23/24) |
 | 2nd | 100% (24/24) | N/A | 50.0% (12/24) | 58.3% (14/24) |
 | 3rd | 100% (24/24) | N/A | 45.8% (11/24) | 58.3% (14/24) |
Total | 1st | 100% (260/260) | 95.9% (142/148) | 74.8% (160/214) | 93.8% (244/260) |
 | 2nd | 98.5% (256/260) | 92.6% (137/148) | 57.5% (123/214) | 78.1% (203/260) |
 | 3rd | 97.7% (254/260) | N/A | 45.3% (97/214) | 77.7% (202/260) |